Alpha Cognition Inc (ACOG)vsAlnylam Pharmaceuticals Inc (ALNY)
ACOG
Alpha Cognition Inc
$5.32
-4.83%
HEALTHCARE · Cap: $124.15M
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 49905% more annual revenue ($3.71B vs $7.43M). ALNY leads profitability with a 8.5% profit margin vs -2.6%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ACOG
Avoid20
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACOG.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -125.6% — below average capital efficiency
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACOG
The strongest argument for ACOG centers on Price/Book.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ACOG
The primary concerns for ACOG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ACOG profiles as a turnaround stock while ALNY is a hypergrowth play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.55 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 20/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is a pioneering biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, with a strong emphasis on Alzheimer's disease. Its lead candidate, ACOG-100, is designed to enhance cognitive function in patients and address significant unmet medical needs within the aging population. Driven by a robust R&D strategy and a proprietary neuroscience platform, Alpha Cognition is strategically positioned to revolutionize patient care in this critical area. As the company continues to advance its clinical pipeline and explore new therapeutic avenues, it represents a compelling opportunity for institutional investors navigating the evolving healthcare landscape.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?